Gliatilin - instructions for use, dose, side effects, contraindications

Pharmacodynamics:Choline alfoscerate as a carrier of choline and phosphatidylcholine precursor has the potential ability to prevent and correct biochemical lesions that are of particular importance among pathogenic factors psychoorganic involutional syndrome, i.e. can influence the reduction in cholinergic transmission and phospholipid composition damaged nerve cell membranes. The chemical formula of choline alphoscerate (containing 40.5% of choline) has the property of metabolic protection and provides the release of the active substance - choline in the brain tissues.Gliatilin positively affects memory functions and cognitive abilities, as well as on the indicators of emotional state and behavior, the deterioration of which was caused by the development of involuntary brain pathology.

Pharmacokinetics:The pharmacokinetic characteristics of the radiolabeled drug were similar in different animal species (rats, dogs, monkeys), as follows: absorption from the gastrointestinal tract completely and quickly; rapid accumulation and distribution in various organs and tissues, including the brain; renal excretion is about 10%, for 96 hours of the administered dose); the concentration of the drug is higher in the brain, in comparison with choline, labeled with tritium.

Indications:

Psycho-organic syndrome against the background of involuntary and degenerative processes in the brain, the consequences of cerebrovascular insufficiency or primary and secondary cognitive impairment in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased concentration of attention.

Violations of behavior and affective sphere in old age: emotional lability, increased irritability,decreased interest. An old pseudo-melancholy.

Contraindications:

Hypersensitivity to choline alfoscerate or auxiliary components of the drug.

Pregnancy, the period of breastfeeding; childhood.

Pregnancy and lactation:The use of the drug during pregnancy and breastfeeding is contraindicated.

Dosing and Administration:

The drug is administered intramuscularly or intravenously (drip, slowly) at a dose of 1000 mg (1 ampoule) per day for 10 days.

Doses and duration of treatment, if necessary and good tolerability can be increased by the attending physician depending on the clinical picture, the features of the course of the disease, the age and tolerability of the drug.

If unwanted reactions appear, a temporary dose reduction is possible (see the "Side effect" section).

Children. The experience of using Gliatilin in children is absent.

Side effects:Perhaps the emergence of nausea (which is mainly a consequence of secondary dopaminergic activation), very rarely possible abdominal pain and short-term confusion. In this case, it is necessary to reduce the used dose of the drug.

Overdose:

There is no information about overdose.

In case of an overdose, symptomatic therapy is indicated. The effectiveness of dialysis is not established.

Interaction:Drug interaction is not established.

Effect on the ability to drive transp. cf. and fur:Care should be taken when driving vehicles or engaging in other activities that require increased concentration and / or speed of psychomotor reactions.

Form release / dosage:Solution for infusion and intramuscular injection 1000 mg / 3 ml.

Packaging:

To 3 ml in ampoules of neutral colorless glass, type I. To 3, 5 or 6 ampoules per contour cell pack. 1 contour pack together with instructions for use in a cardboard box.

3 ampoules per contour cell package. 2 contour squares with instructions for use in cardboard pack.

Storage conditions:At a temperature of no higher than 25 ° C in a dark place. Keep out of the reach of children!

Shelf life:42 months. Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:LP-003090

Date of registration:14.07.2015

Expiration Date:14.07.2020

The owner of the registration certificate:Italfarmaco SpAItalfarmaco SpA Italy

Manufacturer: & nbsp

ITALFARMACO, S.p.A. Italy

Representation: & nbspCBS CJSC LTDCBS CJSC LTDItaly

Information update date: & nbsp26.04.2017

Illustrated instructions

Instructions

Gliatilin (Gliatilin)